Moderna Inc. announced Tuesday that its vaccine for respiratory syncytial virus (RSV) in adults over 60 years old is 84% effective at preventing lower respiratory tract diseases.
Moderna Inc. announced Tuesday that its vaccine for respiratory syncytial virus (RSV) in adults over 60 years old is 84% effective at preventing lower respiratory tract diseases.
About Our Site:
The primary purpose of the site is to provide Real Estate & Mortgage information as it relates to today’s business environment. It can also be used to answer related question you might have about buying, selling, or financing real estate.